In order to observe the curative and side effects in @entity1503 treated with autologous peripheral blood stem cell transplantation (auto-PBSCT) combined with halotype lymphocyte infusion, auto-PBSCs were mobilized, harvested and stored at -196 degrees C from @entity1 in first CR or PR with intensive chemotherapy ( @entity2592 1.0 g/m(2) x 5 days or @entity786 60 mg/kg x 2 days) and @entity1261 . Unpurged auto-PBSCs were infused when @entity1 received the conditioning regimen with @entity1863 , total irradiation or @entity786 . Halotype lymphocytes [mean 5.0 x 10(7)/kg, (4.5 - 6.5) x 10(7)/kg] irradiated with 7.5 Gy were infused to @entity1 when WBCs were more than 1 x 10(9)/L. Hematopoietic recovery and survival of @entity1 were observed. The results showed that in 12 cases accepted this protocol, five @entity1 with @entity981 got to durable remission, of which 2 had durable remission of more than 50 months. One of three @entity1 with @entity1893 IVb reached durable remission, and two relapsed and died on 4 and 6 months after treatment, respectively. Two @entity1860 @entity1 were also achieved durable remission. One @entity1 with @entity1582 relapsed on 36 months later, but he still survived disease-free with treatment of @entity2816 . In a follow-up survey of 25 months, the disease-free survival was 83%. No severe side effects were observed except platelet delayed recovery after halotype lymphocyte infusion. STR-PCR analysis showed that infused donor lymphocytes disappeared in 3 recipients at 72 hours after infusion. It is concluded that auto-PBSCT combined with halotype lymphocyte infusion could decrease the relapse of @entity1503 and improve the effect of auto-PBSCT. Recovery of platelet, however, could be delayed by halotype lymphocyte infusion.

[Treatment of XXXX by peripheral blood stem cell transplantation combined with halotype lymphocyte infusion].

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity981 :: ('MESH:D054198', 'Disease') :: ['acute non-lymphocytic leukemia'] @entity1261 :: ('1440', 'Gene') :: ['G-CSF'] @entity2816 :: ('MESH:D013792', 'Chemical') :: ['thalidomide'] @entity786 :: ('MESH:D003520', 'Chemical') :: ['cyclophosphamide'] @entity2592 :: ('MESH:D003561', 'Chemical') :: ['Ara-C'] @entity1503 :: ('MESH:D006402', 'Disease') :: ['malignant hematologic diseases'] @entity1582 :: ('MESH:D009101', 'Disease') :: ['multiple myeloma'] @entity1863 :: ('MESH:D002066', 'Chemical') :: ['busulfan'] @entity1893 :: ('MESH:D008228', 'Disease') :: ["non-Hodgkin's lymphoma"] @entity1860 :: ('MESH:D015464', 'Disease') :: ['CML']
@entity1503 :: (MESH:D006402,Disease) :: ['malignant hematologic diseases']
